Jefferies Financial Group Begins Coverage on Silence Therapeutics (NASDAQ:SLN)

Jefferies Financial Group started coverage on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $40.00 price target on the stock. SLN has been the subject of several other reports. Morgan Stanley raised their target price on […]